NVO Novo Nordisk A/S

USD 128.40 0.35 0.273331
Icon

Novo Nordisk A/S (NVO) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NYE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 128.40

+0.35 (+0.27)%

USD 554.45B

3.65M

USD 132.22(+2.98%)

USD 106.67 (-16.92%)

Icon

NVO

Novo Nordisk A/S (USD)
COMMON STOCK | NYE
USD 128.40
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 554.45B

USD 106.67 (-16.92%)

USD 128.40

Novo Nordisk A/S (NVO) Stock Forecast

Show ratings and price targets of :
USD 132.22
(+2.98%)

Based on the Novo Nordisk A/S stock forecast from 4 analysts, the average analyst target price for Novo Nordisk A/S is USD 132.22 over the next 12 months. Novo Nordisk A/S’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Novo Nordisk A/S is Slightly Bullish , which is based on 11 positive signals and 6 negative signals. At the last closing, Novo Nordisk A/S’s stock price was USD 128.40. Novo Nordisk A/S’s stock price has changed by -1.10% over the past week, +5.64% over the past month and +65.34% over the last year.

No recent analyst target price found for Novo Nordisk A/S
No recent average analyst rating found for Novo Nordisk A/S

Company Overview Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segmen...Read More

https://www.novonordisk.com

Novo Alle 1, Bagsvaerd, Denmark, 2880

63,370

December

USD

USA

Adjusted Closing Price for Novo Nordisk A/S (NVO)

Loading...

Unadjusted Closing Price for Novo Nordisk A/S (NVO)

Loading...

Share Trading Volume for Novo Nordisk A/S Shares

Loading...

Compare Performance of Novo Nordisk A/S Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for NVO

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Novo Nordisk A/S (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHVN
Biohaven Pharmaceutical Holdin.. -2.33 (-4.09%) USD4.54B N/A -10.03

ETFs Containing NVO

Symbol Name NVO's Weight Expense Ratio Price(Change) Market Cap
PJIO
Pgim ETF Trust - Jennison.. 6.95 % 0.90 % -0.23 (-0.41%) USD0.01B

Frequently Asked Questions About Novo Nordisk A/S (NVO) Stock

Based on ratings from 4 analysts Novo Nordisk A/S's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and hold ratings.

NVO stock's dividend yield is 1.10%. Our analysis grades NVO stock's dividend yield at A+. This means that NVO stock's dividend yield is above 100% of the stocks in the Biotechnology sector in the NYE exchange. Based on this NVO may be a good dividend stock for its sector.

Based on targets from 4 analysts, the average taret price for NVO is USD 132.22 over the next 12 months. The maximum analyst target price is USD 160 while the minimum anlayst target price is USD 110.

NVO stock's Price/Earning ratio is 46.01. Our analysis grades NVO stock's Price / Earning ratio at F. This means that NVO stock's Price/Earning ratio is above 87% of the stocks in the Biotechnology sector in the NYE exchange. Based on this NVO may be a overvalued for its sector.

The last closing price of NVO's stock was USD 128.40.

The most recent market capitalization for NVO is USD 554.45B.

Based on targets from 4 analysts, the average taret price for NVO is projected at USD 132.22 over the next 12 months. This means that NVO's stock price may go up by +2.98% over the next 12 months.

Following are ETFs with the highest allocation to Novo Nordisk A/S's stock :

PJIO

As per our most recent records Novo Nordisk A/S has 63,370 Employees.

Novo Nordisk A/S's registered address is Novo Alle 1, Bagsvaerd, Denmark, 2880. You can get more information about it from Novo Nordisk A/S's website at https://www.novonordisk.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...